Our Top 5 Microcap Stocks
Microcap stocks tend to be an under-researched area… Which increases the odds of discovering attractive investment opportunities.

Just like these 5 which appear to be in an excellent position to see a surge in share price.
>>> See All 5 Here
pixel
Scott T. Reents net worth and biography

Scott Reents Biography and Net Worth

Sr. VP & CFO of AbbVie

Scott Reents is Senior Vice President, Chief Financial Officer, responsible for global financial and business technology operations of the company. He previously served as Vice President, Tax and Treasury.

Mr. Reents joined Abbott in 2008 and held various leadership positions in the company, ultimately serving as Division Vice President, Corporate Tax. After AbbVie’s separation from Abbott in 2013, Mr. Reents led the tax function as Vice President, Tax.

Prior to joining Abbott, Mr. Reents worked in the finance organizations of Pfizer and Pharmacia and began his career at Deloitte.

He earned a bachelor’s degree in finance and economics from the University of Nebraska as well as a Juris Doctor and Master of Business Administration from Washington University.

How old is Scott T. Reents?

Mr. Reents is currently 55 years old. There are 7 older executives and no younger executives at AbbVie. The oldest executive at AbbVie is Mr. Richard A. Gonzalez, Chairman & CEO, who is 68 years old. Learn More on Scott T. Reents' age.

How do I contact Scott T. Reents?

The corporate mailing address for Mr. Reents and other AbbVie executives is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. AbbVie can also be reached via phone at (847) 932-7900. Learn More on Scott T. Reents' contact information.

Has Scott T. Reents been buying or selling shares of AbbVie?

Scott T. Reents has not been actively trading shares of AbbVie during the last quarter. Learn More on Scott T. Reents' trading history.

Who are AbbVie's active insiders?

AbbVie's insider roster includes Carlos Alban (Vice Chairman), Roxanne Austin (Director), Nicholas Donoghoe (SVP), Brian Durkin (VP), Richard Gonzalez (CEO), Henry Gosebruch (EVP), Robert Michael (Vice Chairman), Scott Reents (Sr. VP & CFO ), Timothy Richmond (EVP), Azita Saleki-Gerhardt (EVP), Laura Schumacher (Vice Chairman), Michael Severino (Vice Chairman), Elaine Sorg (SVP), Jeffrey Stewart (EVP), and Carrie Strom (SVP). Learn More on AbbVie's active insiders.

Are insiders buying or selling shares of AbbVie?

During the last year, insiders at the sold shares 16 times. They sold a total of 997,100 shares worth more than $140,525,236.75. The most recent insider tranaction occured on May, 23rd when Vice Chairman Michael Severino sold 79,801 shares worth more than $12,041,970.90. Insiders at AbbVie own 0.1 % of the company. Learn More about insider trades at AbbVie.

Information on this page was last updated on 5/23/2022.

Scott T. Reents Insider Trading History at AbbVie

See Full Table

Scott T. Reents Buying and Selling Activity at AbbVie

This chart shows Mr. Scott T. Reents's buying and selling at AbbVie by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

AbbVie Company Overview

AbbVie logo
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Read More

Today's Range

Now: $163.66
Low: $160.51
High: $163.76

50 Day Range

MA: $148.46
Low: $134.21
High: $163.66

2 Week Range

Now: $163.66
Low: $117.00
High: $175.91

Volume

4,252,299 shs

Average Volume

6,597,847 shs

Market Capitalization

$289.43 billion

P/E Ratio

21.85

Dividend Yield

3.49%

Beta

0.7
Tailor an Options Trading Strategy to Fit Your Needs
This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile.

Take your trading to the next level with the Options Strategy Guide.
Download your FREE Options Strategy Guide Today.
pixel